Pharmaceutical Product Development, a North Carolina-based CRO, is adding more punch to its therapeutics offerings with new leadership overseeing a number of prime areas.
Darell Heiselman, D.O., will lead PPD’s cardiovascular and critical care niches, while David Klein, M.D., has been charged with overseeing endocrinology, metabolism and diabetes.
“In their new roles, Darell and David will help develop cross-functional, integrated product development plans and assist with the design of clinical trials to provide therapeutic, protocol and site development expertise for our clients and their product,” Rob Dow, PPD’s chief medical officer, said in a statement.
Heiselman has been named vice president of global product development. In his 23 years of practice, he developed a critical care center of excellence and performed more than 60 clinical trials in critical care, cardiology, nutritional support and stroke. Before PPD, Heiselman spent 11 years at Eli Lilly as a clinical research physician.
Klein, who is board-certified in pediatrics with a subspecialty board certification in pediatric endocrinology, has also been named a vice president of global product development. He has extensive experience managing diabetes and endocrine clinical trials, as well as trials in the therapeutic areas of pediatrics, rare disease, obesity, lipid metabolism, nonalcoholic steatohepatitis and celiac disease. He previously served as medical director at Medpace and as senior director of clinical development at Mannkind Corp.